Clinical Lymphoma Myeloma and Leukemia This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

SOHO State of the Art Updates and Next Questions |Treatment Approaches for Nodular Lymphocyte-Predominant Hodgkin Lymphoma
Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a rare variant of Hodgkin lymphoma characterized by a persistent risk of relapse but an excellent overall survival. Historically, it was treated similarly to classic Hodgkin lymphoma, but efforts have been made to deintensify treatment due to risk of late toxicity associated with intensive therapy. For patients with completely resected stage IA NLPHL, no further treatment may be considered, particularly for pediatric patients. For those with stage I-II NLPHL without risk factors such as B symptoms, sites>2, or variant pattern histology, lower intensity treatment wi...
Source: Clinical Lymphoma, Myeloma and Leukemia - March 30, 2023 Category: Hematology Authors: Michael S. Binkley, Ranjana H. Advani Tags: Review Article Source Type: research

Treatment approaches for nodular lymphocyte-predominant Hodgkin lymphoma
Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a rare variant of Hodgkin lymphoma characterized by a persistent risk of relapse but an excellent overall survival. Historically, it was treated similarly to classic Hodgkin lymphoma, but efforts have been made to de-intensify treatment due to risk of late toxicity associated with intensive therapy. For patients with completely resected stage IA NLPHL, no further treatment may be considered, particularly for pediatric patients. For those with stage I-II NLPHL without risk factors such as B symptoms, sites>2, or variant pattern histology, lower intensity treatment w...
Source: Clinical Lymphoma, Myeloma and Leukemia - March 30, 2023 Category: Hematology Authors: Michael S. Binkley, Ranjana H. Advani Tags: Review Article Source Type: research

FDA analysis of ineligibility for acute myeloid leukemia clinical trials by race and ethnicity
The objective of this study was to analyze the rates and reasons for trial ineligibility by race and ethnicity in trials of acute myeloid leukemia (AML) submitted to the U.S. Food and Drug Administration (FDA) between 2016-2019. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - March 29, 2023 Category: Hematology Authors: Dianne Pulte, Laura Fernandes, Guo Wei, Ashley Woods, Kelly J. Norsworthy, Nicole Gormley, Bindu Kanapuru, Thomas E. Gwise, Richard Pazdur, Julie Schneider, Marc R. Theoret, Lola A. Fashoyin-Aje, R. Angelo de Claro Tags: Original Study Source Type: research

Real-World Patient Characteristics, Treatment Patterns, and Outcomes for Patients With Stage III or IV Classic Hodgkin Lymphoma Treated With Frontline ABVD: A Retrospective Database Review in the United States
: In newly diagnosed stage III/IV classic Hodgkin lymphoma (cHL), A+AVD (brentuximab vedotin, doxorubicin, vinblastine, dacarbazine) improved overall survival (OS) versus ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine). As clinical trial and real-world populations may differ, real-world treatment characteristics and OS (rwOS) were assessed for patients with stage III/IV cHL treated with frontline ABVD. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - March 29, 2023 Category: Hematology Authors: Allison Winter, Nicholas Liu, Andy Surinach, Michelle Fanale, Kristina S. Yu, Mayur Narkhede Tags: Original Study Source Type: research

Ixazomib Versus Placebo as Postinduction Maintenance Therapy in Newly Diagnosed Multiple Myeloma Patients: An Analysis by Age and Frailty Status of the TOURMALINE-MM4 Study
This TOURMALINE-MM4 secondary analysis was performed to determine if the progression-free survival (PFS) benefit observed in newly-diagnosed multiple myeloma (NDMM) patients with maintenance ixazomib versus placebo was driven by a particular subgroup of patients. PFS benefit with ixazomib versus placebo was seen across all age and frailty status subgroups. Ixazomib prolonged PFS across the heterogeneous population of NDMM patients. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - March 28, 2023 Category: Hematology Authors: Sara Bringhen, Lud ěk Pour, Reuben Benjamin, Sebastian Grosicki, Chang-Ki Min, Danielle Leao C． de Farias, Alexander Vorog, Richard J. Labotka, Bingxia Wang, Dasha Cherepanov, Lauren E. Cain, Sudhakar Manne, S. Vincent Rajkumar, Meletios A. Dimopoulos Source Type: research

Clinical analysis of pediatric T-cell acute lymphoblastic leukemia using the MRD-oriented strategy system
Pediatric T-cell acute lymphoblastic leukemia (T-ALL) has historically been associated with a poor prognosis. However, prognostic indicators and methods of treatment used for T-ALL remain controversial. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - March 28, 2023 Category: Hematology Authors: Yu-juan Xue, Yu Wang, Ai-dong Lu, Yue-ping Jia, Ying-xi Zuo, Ming-ming Ding, Hui-min Zeng, Le-ping Zhang Tags: Review Article Source Type: research

Ixazomib Versus Placebo as Post-Induction Maintenance Therapy in Newly Diagnosed Multiple Myeloma Patients: An Analysis by Age and Frailty Status of the TOURMALINE-MM4 Study
Multiple myeloma (MM) is typically a disease of the elderly, with a median age of 69 years at diagnosis and more than 30% of patients aged ≥ 75 years.1,2 Despite substantial advances in treatment over the past decade,3 elderly patients with MM typically have reduced survival and impaired quality of life (QoL) compared to younger patients, often as a consequence of comorbidities, increased toxicity, and early treatment discontinuation .2,4 Consequently, there remains a substantial unmet need in this patient population for more feasible and tolerable therapies allowing for prolonged treatment. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - March 28, 2023 Category: Hematology Authors: Sara Bringhen, Lud ěk Pour, Reuben Benjamin, Sebastian Grosicki, Chang-Ki Min, Danielle Leao C. de Farias, Alexander Vorog, Richard J. Labotka, Bingxia Wang, Dasha Cherepanov, Lauren E. Cain, Sudhakar Manne, S. Vincent Rajkumar, Meletios A. Dimopoulos Source Type: research

A Phase II, Open-Label Study of an Accelerated Infusion Rate of Daratumumab in Patients with Relapsed and Refractory Multiple Myeloma
Daratumumab is an anti-CD38 monoclonal antibody initially approved as a single agent for the treatment of relapsed and refractory multiple myeloma. The infusion-related reactions (IRRs) commonly seen with intravenous daratumumab have been managed by prolonging the first infusion, temporarily stopping/slowing the rate if reactions occur and using adequate pre- and post-infusion medications. Several retrospective studies have evaluated shorter infusions after ≥2 prior doses administered at the standard rates. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - March 24, 2023 Category: Hematology Authors: Julie Stakiw, Shruthi Kodad, Richard LeBlanc, Michael Sebag, Annette E. Hay, Vishal Kukreti, Julie C ôté, Fernando Camacho, Molei Fu, Engin Gul, Donna Reece Tags: Original Study Source Type: research

Treatment Discontinuation Patterns for Patients with Chronic Lymphocytic Leukemia in Real-World Settings: Results from a Multi-Center International Study
This study assessed treatment discontinuation patterns and reasons among chronic lymphocytic leukemia (CLL) patients initiating first-line (1L) and second line (2L) treatments in real-world settings. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - March 23, 2023 Category: Hematology Authors: Mazyar Shadman, Beenish S. Manzoor, Kavita Sail, Hande H. Tuncer, John N. Allan, Chaitra Ujjani, Nnadozie Emechebe, Rajesh Kamalakar, Catherine C. Coombs, Lori Leslie, Paul M. Barr, Jennifer R. Brown, Toby A. Eyre, Alexandros Rampotas, Anna Schuh, Nicole Source Type: research

Immune Reconstitution and Vaccinations in Multiple Myeloma: A report from the 19th International Myeloma Society Annual Workshop
Given the significance of the immune system and the important role of therapies within the context of the immune system in plasma cell disorders, the International Myeloma Society (IMS) annual workshop convened a session dedicated to this topic. A panel of experts covered various aspects of immune reconstitution and vaccination. The top oral presentations were highlighted and discussed. This is a report of the proceedings (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - March 22, 2023 Category: Hematology Authors: Evangelos Terpos, Paola Neri, Niels WCJ van de Donk, Mattia D'Agostino, Samir Parekh, Sundar Jagannath, Heinz Ludwig, David E. Avigan, Madhav V. Dhodapkar, Noopur S. Raje Tags: Review Article Source Type: research

Editorial Board
(Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - March 21, 2023 Category: Hematology Source Type: research

Table of Contents
(Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - March 21, 2023 Category: Hematology Source Type: research

Management of chronic myeloid leukemia patients in later lines: the role of ponatinib and new compounds
Limited therapeutic options and poor response probability still represent some unresolved issue in later lines chronic myeloid leukemia (CML) patients. In addition, sequential treatment is associated with reduced overall survival and may select new mutation, including the T315I, further reducing the therapeutic chances: outside the United States, ponatinib and allogenic stem cell transplant are the only available options. In the last decade, ponatinib improved outcomes in third-line patients, although limited by the risk of severe adverse occlusive events. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - March 18, 2023 Category: Hematology Authors: Emilia Scalzulli, Ida Carmosino, Alessandro Costa, Maria Laura Bisegna, Maurizio Martelli, Massimo Breccia Source Type: research

Impact of Disease Progression, Line of Therapy, and Response on Health-Related Quality of Life in Multiple Myeloma: A Systematic Literature Review
This systematic literature review (SLR) was conducted to better understand the impact of disease progression, line of therapy, and clinical response on health-related quality of life (HRQoL) in patients with multiple myeloma (MM). (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - March 17, 2023 Category: Hematology Authors: Rafael Fonseca, Diana Tran, Alyshia Laidlaw, Emily Rosta, Manvir Rai, Joana Duran, Eric M. Ammann Tags: Review Article Source Type: research

SOHO State-of-the-Art Updates and Next Questions: A Modern Approach to the Systemic Treatment of Advanced CTCL
The term cutaneous T-cell lymphoma (CTCL) is a general term for T-cell lymphomas that are found primarily in skin. The most common CTCL entities, mycosis fungoides and Sezary syndrome are incurable diseases with a plethora of conventional treatment options. In the past treatment options have been selected primarily according to stage. Given newer targeted therapies with varied response in different body compartments, we suggest a compartment-guided algorithm that may enhance response rates directing the selection of the most efficacious treatment options. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - March 16, 2023 Category: Hematology Authors: Danielle Brazel, Lauren Pinter-Brown Tags: Review Article Source Type: research